BR112015027282A8 - formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet - Google Patents

formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet Download PDF

Info

Publication number
BR112015027282A8
BR112015027282A8 BR112015027282A BR112015027282A BR112015027282A8 BR 112015027282 A8 BR112015027282 A8 BR 112015027282A8 BR 112015027282 A BR112015027282 A BR 112015027282A BR 112015027282 A BR112015027282 A BR 112015027282A BR 112015027282 A8 BR112015027282 A8 BR 112015027282A8
Authority
BR
Brazil
Prior art keywords
fenfluramine
dravet syndrome
treatment
kit
liquid formulation
Prior art date
Application number
BR112015027282A
Other languages
English (en)
Other versions
BR112015027282A2 (pt
Inventor
Ceulemans Berten
Lagae Lieven
Original Assignee
Univ Leuven Kath
Univ Hospital Antwerp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50729472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015027282(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Leuven Kath, Univ Hospital Antwerp filed Critical Univ Leuven Kath
Publication of BR112015027282A2 publication Critical patent/BR112015027282A2/pt
Publication of BR112015027282A8 publication Critical patent/BR112015027282A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

resumo patente de invenção: "fenfluramina para uso no tratamento de síndrome de dravet". a presente invenção refere-se a uma dose eficaz de fenfluramina ou sal farmaceuticamente aceitável da mesma para uso em um método para tratamento e/ou prevenção da síndrome de dravet em um paciente como um paciente diagnosticado anteriormente com síndrome de dravet.
BR112015027282A 2013-05-03 2014-05-01 formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet BR112015027282A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/887,014 US9549909B2 (en) 2013-05-03 2013-05-03 Method for the treatment of dravet syndrome
PCT/EP2014/058954 WO2014177676A1 (en) 2013-05-03 2014-05-01 Fenfluramine for use in the treatment of dravet syndrome

Publications (2)

Publication Number Publication Date
BR112015027282A2 BR112015027282A2 (pt) 2017-07-25
BR112015027282A8 true BR112015027282A8 (pt) 2019-12-24

Family

ID=50729472

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015027282A BR112015027282A8 (pt) 2013-05-03 2014-05-01 formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet

Country Status (17)

Country Link
US (13) US9549909B2 (pt)
EP (2) EP3329909B1 (pt)
JP (3) JP6441313B2 (pt)
AU (4) AU2014261329B2 (pt)
BR (1) BR112015027282A8 (pt)
CA (1) CA2909335C (pt)
CY (1) CY1124298T1 (pt)
DK (2) DK3329909T3 (pt)
ES (2) ES2863929T3 (pt)
HR (1) HRP20210819T1 (pt)
HU (1) HUE054577T2 (pt)
LT (1) LT3329909T (pt)
NO (1) NO3092234T3 (pt)
PL (2) PL3329909T3 (pt)
PT (2) PT3329909T (pt)
SI (1) SI3329909T1 (pt)
WO (1) WO2014177676A1 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
AU2015326472B2 (en) 2014-09-29 2020-05-28 Zogenix International Limited Control system for control of distribution of medication
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
EP3632434A1 (en) * 2015-02-25 2020-04-08 The Regents of the University of California The 5ht agonist clemizole for use in treating disorders
JP6668045B2 (ja) * 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
EP3340971B1 (en) * 2015-08-24 2024-03-13 Zogenix International Limited Methods of treating lennox-gastaut syndrome using fenfluramine
WO2017060731A1 (en) 2015-10-09 2017-04-13 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
EP3933041B1 (en) 2015-12-14 2024-01-31 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant retardation
RU2020128323A (ru) 2015-12-22 2020-10-06 Зодженикс Интернэшнл Лимитед Фенфлураминовые композиции и способы их получения
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
IL290727B2 (en) 2016-08-24 2023-12-01 Zogenix International Ltd A formulation for inhibiting the formation of 5–HT 2B agonists and methods of using it
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
US20180092864A1 (en) * 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
EP3528807A4 (en) * 2016-11-22 2020-06-17 Ovid Therapeutics Inc METHOD FOR TREATING DEVELOPMENT DISORDERS AND / OR FALLS WITH FLUPIRTIN
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
MX2019012285A (es) 2017-04-13 2020-11-06 Ovid Therapeutics Inc Metodos de tratamiento de encefalopatias del desarrollo.
US20200170965A1 (en) * 2017-05-09 2020-06-04 Zogenix International Limited Methods of treating doose syndrome using fenfluramine
SI3673080T1 (sl) 2017-08-25 2024-03-29 Stoke Therapeutics, Inc. Protismiselni oligomeri za zdravljenje bolezenskih stanj in bolezni
WO2019067413A1 (en) * 2017-09-26 2019-04-04 Zogenix International Limited USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
US20190091179A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US20190091174A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Method of reducing seizure type experienced by a dravet patient
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
JP2021526507A (ja) * 2018-05-11 2021-10-07 ゾゲニクス インターナショナル リミテッド 発作により誘発される突然死を処置するための組成物および方法
WO2019241005A1 (en) * 2018-06-14 2019-12-19 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
US20210113495A1 (en) * 2018-07-10 2021-04-22 Zogenix International Limited Method of treating epilepsy or epileptic encephalopathy with fenfluramine in patients without pulmonary hypertension
MA53329A (fr) * 2018-07-27 2022-03-02 Xenon Pharmaceuticals Inc Méthodes de traitement de l'épilepsie
US20220133652A1 (en) * 2019-02-25 2022-05-05 Zogenix International Limited A formulation for improving seizure control
CN111944835B (zh) * 2019-05-14 2022-03-29 南通大学 一种突变型gabrg2转基因斑马鱼癫痫模型的构建方法及应用
JP2022546700A (ja) * 2019-08-30 2022-11-07 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル ミトコンドリア機能障害に関連する神経変性障害の治療のための銅－ａｔｓｍ
CA3153099A1 (en) * 2019-09-17 2021-03-25 Zogenix International Limited Methods of treating epileptic patients with fenfluramine
US20210299064A1 (en) 2020-02-05 2021-09-30 Zogenix International Limited Method of treating patients with lennox-gastaut syndrome
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
JP2023525799A (ja) 2020-05-11 2023-06-19 ストーク セラピューティクス，インク． 状態及び疾患の治療のためのｏｐａ１アンチセンスオリゴマー
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1413070A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of - norfenfluramine and - fenfluramine and salts thereof
GB1413078A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
US4452815A (en) 1980-06-16 1984-06-05 Massachusetts Institute Of Technology Method of utilizing d,l-fenfluramine for modifying feeding behavior
IT1238686B (it) 1990-02-09 1993-09-01 Lab Mag Spa Procedimento per la preparazione di levo e destro fenfluramina
FR2684552B1 (fr) 1991-12-06 1995-04-28 Adir Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants.
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
EP1411955A4 (en) 2001-07-31 2006-07-05 Wyeth Corp SUCRALOSE FORMULATIONS FOR COVERING UNANGEAN TASTE
US6599901B1 (en) 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
WO2006125774A1 (en) 2005-05-25 2006-11-30 Janssen Pharmaceutica N.V. Pediatric formulation of topiramate
GB0515090D0 (en) 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
EP1937255A4 (en) 2005-09-14 2013-06-26 Univ Witwatersrand Jhb PHARMACEUTICAL COMPOSITION
US8039468B2 (en) 2006-08-31 2011-10-18 The Governors Of The University Of Alberta Method of inhibition of respiratory depression using positive allosteric AMPA receptor modulators
EP2254577A1 (en) 2007-12-26 2010-12-01 Eisai R&D Management Co., Ltd. Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
CA2749273C (en) 2008-01-09 2018-09-04 Charleston Laboratories, Inc. Pharmaceutical oral dosage form comprising a triptan and an antiemetic
AU2009301296A1 (en) 2008-10-09 2010-04-15 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Liquid pharmaceutical formulation containing paracetamol
CA2758774C (en) 2009-04-15 2015-02-03 Research Triangle Institute Monoamine reuptake inhibitors
US9453027B2 (en) 2009-07-27 2016-09-27 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
TW201127375A (en) 2010-01-08 2011-08-16 Eurand Inc Taste masked topiramate composition and an orally disintegrating tablet comprising the same
AU2011283008A1 (en) 2010-07-30 2013-01-24 Merck Sharp & Dohme Corp. Inhibition of CYP3A drug metabolism
US20120270848A1 (en) 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
MX2013003832A (es) 2010-10-26 2013-10-01 Alpharma Pharmaceuticals Llc Formulaciones y metodos para atenuar la depresion respiratoria inducida por sobredosis de opioides.
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
SG11201503505QA (en) 2012-11-15 2015-06-29 Galleon Pharmaceuticals Inc Novel orally bioavailable breathing control modulating compounds, and methods of using same
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
WO2015026849A1 (en) 2013-08-19 2015-02-26 The Regents Of The University Of California Compounds and methods for treating an epileptic disorder
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
EP3632434A1 (en) 2015-02-25 2020-04-08 The Regents of the University of California The 5ht agonist clemizole for use in treating disorders
WO2017003822A1 (en) 2015-06-30 2017-01-05 Galleon Pharmaceuticals, Inc. Novel breathing control modulating compounds, and methods of making and using same
WO2017015309A1 (en) 2015-07-22 2017-01-26 John Hsu Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
EP3340971B1 (en) 2015-08-24 2024-03-13 Zogenix International Limited Methods of treating lennox-gastaut syndrome using fenfluramine
US20170071949A1 (en) 2015-09-14 2017-03-16 Zogenix International Limited Combination treatment of specific forms of epilepsy
RU2020128323A (ru) 2015-12-22 2020-10-06 Зодженикс Интернэшнл Лимитед Фенфлураминовые композиции и способы их получения
IL290727B2 (en) 2016-08-24 2023-12-01 Zogenix International Ltd A formulation for inhibiting the formation of 5–HT 2B agonists and methods of using it
US20180092864A1 (en) 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
US20200170965A1 (en) 2017-05-09 2020-06-04 Zogenix International Limited Methods of treating doose syndrome using fenfluramine

Also Published As

Publication number Publication date
NO3092234T3 (pt) 2018-07-14
US20140343044A1 (en) 2014-11-20
US20160136114A1 (en) 2016-05-19
PL2991637T3 (pl) 2018-07-31
US20210121479A1 (en) 2021-04-29
US20170151213A1 (en) 2017-06-01
US9603814B2 (en) 2017-03-28
ES2863929T3 (es) 2021-10-13
WO2014177676A1 (en) 2014-11-06
US9603815B2 (en) 2017-03-28
US20170151194A1 (en) 2017-06-01
AU2019203448A1 (en) 2019-06-06
AU2014261329A1 (en) 2015-11-05
HRP20210819T1 (hr) 2021-08-20
BR112015027282A2 (pt) 2017-07-25
JP2016518387A (ja) 2016-06-23
US9549909B2 (en) 2017-01-24
CY1124298T1 (el) 2022-07-22
US20200030341A1 (en) 2020-01-30
EP2991637B1 (en) 2018-03-07
US20140343161A1 (en) 2014-11-20
AU2014261329B2 (en) 2019-02-21
HUE054577T2 (hu) 2021-09-28
EP3329909A1 (en) 2018-06-06
JP6441313B2 (ja) 2018-12-19
US9610260B2 (en) 2017-04-04
ES2666657T3 (es) 2018-05-07
PT3329909T (pt) 2021-05-14
LT3329909T (lt) 2021-07-12
US20170151214A1 (en) 2017-06-01
CA2909335C (en) 2021-05-18
US10478442B2 (en) 2019-11-19
US20140329908A1 (en) 2014-11-06
US20140343162A1 (en) 2014-11-20
US10478441B2 (en) 2019-11-19
US20170151259A1 (en) 2017-06-01
US20170151257A1 (en) 2017-06-01
JP6655156B2 (ja) 2020-02-26
AU2019203832A1 (en) 2019-06-20
JP6966584B2 (ja) 2021-11-17
JP2019048862A (ja) 2019-03-28
CA2909335A1 (en) 2014-11-06
PT2991637T (pt) 2018-04-24
AU2019203448B2 (en) 2020-08-06
AU2019203832B2 (en) 2020-10-15
AU2020267264A1 (en) 2020-12-17
SI3329909T1 (sl) 2021-08-31
EP3329909B1 (en) 2021-03-17
DK2991637T3 (en) 2018-05-07
EP2991637A1 (en) 2016-03-09
DK3329909T3 (da) 2021-04-19
PL3329909T3 (pl) 2021-10-11
JP2020063309A (ja) 2020-04-23
US20220160727A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
BR112016012713A2 (pt) Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
BR112016002465A2 (pt) terapia da combinação para o tratamento de câncer
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
BR112015001847A8 (pt) Composições e tratamento para doenças e distúrbios nos olhos
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112013029256A2 (pt) "combinações farmacêuticas para uso no tratamento de pacientes com diabetes tipo 2, método de tratamento, e usos de lixisenatida e metformina".
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112019008384A2 (pt) composição farmacêutica, processos para tratamento e seus usos
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112015027477A8 (pt) bolus, seus usos, e kit
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112014030534A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de doenças associadas com óxido nítrico sintase induzível elevada

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]